One size does not fit all, reports Certara’s CEO, Edmundo Muniz, and in situations when pharmacokinetic data may be difficult or impossible to obtain, modeling and simulation will stand alone.
Read MoreAuthors: Edmundo Muniz
The Game Changer
Modeling and simulation in drug development could change the commercial and regulatory landscape forever… and can deliver significant business, scientific and clinical value to companies.
Read MoreDrug Development through Modeling and Simulation – the Business Case
The new blockbuster: well-defined patient populations bring efficiency to drug development and higher commercial value to precision drugs (labels).
Read MoreThe Future of Drug Development is Virtualized and Personalized
Today, drug development is carried out in human subjects and animals. However, as computing power and the number of sophisticated technology platforms grow exponentially, and our knowledge of human health and disease increases, the virtualization of clinical research and development will grow steadily.
Read MoreBest Practices in Drug Development Modeling and Simulation
The use of modeling and simulation (M&S) in drug development has evolved from being a research nicety to a regulatory necessity. This paper provides a compilation of best practices to systematically leverage the many benefits of M&S across a drug development program.
Read More